Edison issues report on BB Biotech (BION)
|
Edison Investment Research Limited
London, UK, 28 October 2025
Edison issues report on BB Biotech (BION) Edison issues report on BB Biotech (SIX: BION) BB Biotech (BION) delivered strong Q325 results, underpinned by its focus on innovative biotech companies with differentiated clinical pipelines and promising long-term potential. NAV increased 24.0% (in CHF terms) and its share price rose 20.0%, both comfortably outperforming BION’s benchmark, the Nasdaq Biotech Index (15.7%). The most recent quarter benefited from improving macroeconomic conditions, including the Federal Reserve’s first rate cut in September. The sector outlook remains favourable, with M&A expected to be a key performance driver as big pharmaceutical companies replenish their pipelines ahead of a looming patent cliff. Several core portfolio holdings achieved significant clinical and regulatory milestones, supporting BION’s momentum, and others are anticipated before year-end, serving as potential near-term catalysts for portfolio performance. Click here to read the full report. All reports published by Edison are available to download free of charge from its website Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: +44 (0)20 3077 5700 Connect with Edison on:
LinkedIn www.linkedin.com/company/edison-group-/ YouTube www.youtube.com/edisonitv
Dissemination of a CORPORATE NEWS, transmitted by EQS Group. |
2219832 28-Oct-2025
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e | ||
| Sales1 | 683,90 | 0,00 | 1,28 | 0,57 | 119,28 | 0,00 | 0,00 | |
| EBITDA1,2 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | 0,00 | |
| EBIT1,4 | 637,31 | -390,46 | -361,02 | -222,29 | 86,01 | 0,00 | 0,00 | |
| EBIT-Margin5 | 93,19 | 0,00 | -28.204,69 | -38.998,25 | 72,11 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 637,24 | -390,53 | -362,83 | -222,41 | 80,66 | 0,00 | 0,00 | |
| Net-Margin6 | 93,18 | 0,00 | -28.346,09 | -39.019,30 | 67,62 | 0,00 | 0,00 | |
| Cashflow1,7 | 241,97 | -91,44 | 234,37 | 234,97 | 323,67 | 0,00 | 0,00 | |
| Earnings per share8 | 11,51 | -7,05 | -6,59 | -4,05 | 1,47 | 11,23 | 3,60 | |
| Dividend per share8 | 3,32 | 3,67 | 2,88 | 2,10 | 1,91 | 2,42 | 2,05 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Deloitte
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| BB Biotech | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A0NFN3 | CH0038389992 | AG | 2.891,88 Mio € | 10.12.1997 | Kaufen | 8FVCMJWM+W3 |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 11,60 | 10,14 | 1,14 | -236,20 | 1,22 | 8,93 | 24,24 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 2,10 | 1,91 | 2,42 | 4,64% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 19.03.2026 | 24.04.2026 | 24.07.2026 | 23.10.2026 | 20.02.2026 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +9,02% | +35,70% | +7,63% | +30,01% | +998,95% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
